# Avacta Group geared up to bring high quality, high volume lateral flow antigen test to market (Interview)

- Link: https://www.directorstalkinterviews.com/avacta-group-geared-up-to-bring-high-quality-high-volume-lateral-flow-antigen-test-to-market-interview/412959839
- Published: 2021-02-08T12:37:18+00:00
- Author: Giles

**[Avacta](https://www.directorstalkinterviews.com/company/avacta-group-plc/avct.l)
Group plc** ([LON:AVCT](https://www.directorstalkinterviews.com/ftse-company/avacta-group-plc/avct.l))
CEO Alastair Smith joins DirectorsTalk to discuss its partnership with Mologic. 
Alastair talks us through the details of the agreement, expands on the additional
manufacturing capacity, explains how it will develop develop other diagnostic tests
including a second generation COVID test and tells us when we can expect an update
in respect of the clinical evaluation of the lateral flow test.

Avacta Group is developing novel cancer immunotherapies combining its two proprietary
platforms – Affimer® biotherapeutics and pre|CISIONTM tumour targeted chemotherapy.
With this approach, the Company aims to address the lack of a durable response to
current immunotherapies experienced by most patients. The Company’s therapeutics
development activities are based in Cambridge, UK.

The Company benefits from near-term revenues generated from Affimer reagents for
diagnostics, bioprocessing and research, through a separate business unit based 
in Wetherby, UK.

Share on: